The fifth vital sign

The fifth vital sign was the medical movement to assess pain alongside blood pressure, heart rate, respiratory rate, and temperature. It answered a genuine concern: pain had often been undertreated, and patients’ accounts of suffering were too readily discounted. But the effort to make pain visible and actionable also created a standardized measure whose apparent precision exceeded its ability to capture different experiences. In the account of the opioid crisis, that tension mattered: the new priority for pain care coincided with wider opioid prescribing and gave Purdue Pharma an opportunity to present its product as a compassionate answer to a clinical obligation.

From neglected pain to a clinical priority

The change gathered force around the 1996 introduction of OxyContin. Doctors, hospitals, and accreditation bodies were adopting the idea that pain should count as a fifth vital sign, giving it a place beside the familiar measurements of bodily function. A 2000 report in The New York Times reflected the concern behind the movement through the case of an older nursing-home resident with severe osteoporosis and pulmonary disease who had been left in pain and given only Tylenol. The problem was not imaginary: many health workers, the article observed, wrongly feared that adequate relief could leave patients addicted.

That push to take pain seriously developed alongside a broader shift toward treating patients as health-care consumers. Formal patient surveys, including those run by Press Ganey, allowed patients to rate their care, while doctors and hospitals competed for higher scores. Because reimbursement could be affected by those evaluations, pain relief became more than a matter of clinical judgment; it could influence how patients assessed a provider and how institutions fared. The campaign thus joined an ethical demand to relieve suffering with institutional incentives to demonstrate that pain had been addressed.

Turning pain into a standard

In 1999, the Joint Commission on Accreditation of Healthcare Organizations approved mandatory standards for pain assessment and treatment, pushing the new priority into hospital practice. The standards made assessment more systematic, but they did not settle what adequate relief meant. Nor did they resolve whether a patient’s report could be converted into a dependable numerical measure. Pain is not directly visible, and a scale could make it look objective without making experiences comparable: a transition in labor and a stubbed toe might each receive a rating of ten, depending on the person’s tolerance.

The measure’s administrative usefulness could therefore be mistaken for clinical certainty. A number was easy to record and procedures were easier to standardize around it, but later experts acknowledged that the scale’s objectivity was largely an appearance. The book also notes that reliance on pain scales did not correlate with improved patient outcomes, while it did have the effect of increasing opioid prescribing and opioid abuse. The fifth vital sign could make pain harder to ignore, yet the act of measuring it did not itself establish which treatment would help, how much relief was enough, or what risks followed from medication.

A standard meets a sales strategy

The new standards also opened a commercial opportunity. In a budget plan, Purdue Pharma described the prospect of presenting itself as a leader in helping hospitals meet the Joint Commission requirements, through pain-assessment and pain-management materials. The company planned to distribute $300,000 worth of OxyContin-branded scroll pens, $225,000 in resource binders, and $290,000 in wall charts and clipboards bearing the pain-as-fifth-vital-sign message. The supplies were not merely generic educational tools: the branded materials placed the company’s product and identity inside the very institutional setting where pain assessment was becoming routine.

This effort fitted Purdue Pharma’s larger promotion of OxyContin. David Haddox, the company’s medical spokesman, claimed that the addiction risk for patients taking opioids as prescribed was one-half of 1 percent; a 1996 company training session described doctor-caused addiction as exquisitely rare. Sales representatives carried the message nationally, presenting OxyContin as safe and appropriate not only for cancer pain but also for conditions such as back injuries, dental surgery, bronchitis, and temporomandibular joint disorder. The fifth-vital-sign campaign did not by itself dictate a particular drug, but its emphasis on identifying and treating pain gave Purdue Pharma a receptive institutional context in which to promote opioids as responsible care.

The broader promotion climate reinforced that overlap. After the loosening of federal rules on pharmaceutical advertising, drug advertising rose from $360 million in 1995 to $1.3 billion in 1998, while companies increasingly used gifts to influence physicians. Purdue Pharma targeted doctors according to their prescribing patterns, drawing on data from IMS Health and sending more visits to those judged most likely to prescribe. In rural communities, representatives promoted OxyContin’s potency and longer action to physicians already prescribing painkillers such as Percocet and Vicodin. The clinical language of pain assessment and the commercial language of product promotion could consequently travel together, even though one concerned standards of care and the other sales.

Consequences and retrospective judgment

Physicians later described the pressure to make pain a priority as a force that changed prescribing practice. John Burton, head of emergency medicine for Carilion Clinic, recalled that doctors were told to take pain more seriously and that opioid prescribing rose without a sufficient understanding of the consequences. He also remembered telling residents that a patient could not become dependent on a two-week supply of opioid pills, a belief he later recognized as wrong. His recollection shows how a compassionate correction to undertreatment could coexist with mistaken confidence about medication risk.

The book does not treat the movement’s original concern as a pretext: patients really had been left in pain, and fear of addiction had contributed to inadequate relief. Its criticism falls on the way a complex experience was turned into a standardized score, then embedded in institutional requirements and commercial messaging without a clear definition of adequate treatment or a comparable account of risk. The fifth vital sign consequently carries a double meaning. It marks an effort to recognize suffering that medicine had overlooked, and it records how that recognition could be made measurable, incentivized, and commercially useful before its consequences were understood.